Cronos Group Stock And Other Penny Shares With Room To Surprise

Inflation worries, higher bond yields and volatile energy prices are pushing many investors to look beyond the usual large caps and consider where the next potential multi-bagger might come from. That is where the Elite Penny Stocks screener can help, by focusing on smaller companies that still have the balance sheet strength to fund their growth plans without running out of cash too soon. In this article, you will see three of the most interesting stocks from the screener and how they fit into a world where inflation, interest rates and commodity shocks are shaping returns across every sector.

Cronos Group (TSX:CRON)

Overview: Cronos Group is a cannabinoid company that cultivates, produces, distributes, and markets cannabis products such as dried flower, pre-rolls, oils, vapes, edibles, and tinctures under brands like Spinach, Lord Jones, Lit, and Peace Naturals across Canada, Israel, and other international markets.

Operations: Cronos Group generates about $159.5 million from cultivation, manufacture, and marketing of cannabis and cannabis derived products, with revenue of $95.6 million from Canada, $46.7 million from Israel, and $17.3 million from other countries.

Market Cap: CA$1.46b

Cronos Group stands out in the penny stock space because it combines recognised cannabis brands, exposure to medical and wellness markets in Canada and overseas, and a sizeable cash position with no debt, which gives it options that many smaller peers do not have. Some market commentators focus on the potential for earnings to change as the company concentrates on higher margin products and international sales, and share repurchases indicate management’s willingness to return excess capital. On the other hand, Cronos is still working toward consistent profitability, operates in a heavily regulated sector, and carries a relatively high P/S multiple, so execution on expansion and cost control is important. For investors who understand and accept those risks, the full story behind this setup may warrant closer examination.

Cronos Group’s cash rich balance sheet and lack of debt could be masking what really matters for this cannabis stock, so walk through the Cronos Group financial health report and see where the real pressure points might sit.

CEMATRIX (TSX:CEMX)

Overview: CEMATRIX manufactures and installs cellular concrete across North America for infrastructure, industrial, and commercial projects, supplying lightweight, pumpable concrete used in roads, bridges, retaining walls, utilities, and soil stabilization.

Operations: CEMATRIX generates about CA$45.7 million from supplying and placing cellular concrete, with CA$11.7 million from Canada and CA$34.1 million from the United States.

Market Cap: CA$73.4 million

CEMATRIX may appeal to investors seeking exposure to infrastructure and sustainable building materials, as its cellular concrete is used in projects that prioritize lighter loads, insulation, and lower carbon profiles. The company reports a record backlog and ongoing contract wins across Canada and the US. At the same time, earnings can fluctuate with project timing, competition affects its valuation, and the business relies on external borrowing, so the quality of future contracts and margin discipline are important alongside the growth narrative. Overall, CEMATRIX presents a mix of growth expectations, recent buybacks, and notable risks that investors need to evaluate carefully.

CEMATRIX’s growing backlog and share buybacks hint at a story that the share price may not fully reflect yet, so walk through the analysis report for CEMATRIX to see what the contract mix could be setting up next.

Cannara Biotech (TSX:LOVE)

Overview: Cannara Biotech is a vertically integrated Canadian cannabis producer that grows, processes, and sells indoor cannabis and derivative products under the TRIBAL, Nugz, and ORCHID CBD brands, while also operating a smaller real estate segment.

Operations: Cannara Biotech generates about CA$108.8 million from cannabis operations and CA$3.9 million from real estate, with roughly CA$113.0 million of revenue coming from Canada.

Market Cap: CA$176.8 million

Cannara Biotech offers a mix of scale, brands, and optionality that is unusual in the penny stock bracket, with national retail share growth, 20 consecutive quarters of positive adjusted EBITDA, and a focus on premium products at sharp prices. At the same time, capacity additions, high inventory and heavy reliance on Quebec create real execution risk if demand outside its core province or in export markets does not build as planned, and recent pressure on margins shows that mix and pricing still matter. For investors willing to weigh those trade offs, valuation metrics, analyst expectations and upcoming product launches indicate there is more to this story than the headline numbers alone.

Cannara Biotech’s mix of national retail share, premium positioning and consistent adjusted EBITDA suggests the headline story might be incomplete, so walk through the analyst forecasts for Cannara Biotech to see what the next phase could really hinge on.

The three stocks covered here are only a starting point, with the full Elite Penny Stocks screener uncovering 8 more companies that share the same cash focused discipline and potential for compelling growth stories. Unlock deeper insights by using Simply Wall St to filter for the specific catalysts and narratives that matter to you, so you can identify and analyze the highest conviction penny stock ideas for your watchlist.

Take Control of Your Investment Journey

If Cannara Biotech or any of these companies have caught your attention, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value and track any new developments as they happen. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.

Seeking Fresh Alternatives Before Momentum Flies

Fresh ideas move fast and early momentum can be gone before most investors even notice. Scan these under-the-radar stock groups while it matters and act now.

• Spot sturdy balance sheets before the crowd by reviewing the curated list of solid balance sheet and fundamentals (12 results) that keeps weaker stories from crowding out the standouts.
• Ride structural shifts in power demand with the focused 34 power grid technology and infrastructure stocks and see which infrastructure stocks may be lining up for lasting grid upgrade themes.
• Target resilient income streams by checking the hand picked 6 dividend fortresses that concentrates on higher yielding companies working to pair payouts with balance sheet strength.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com